The frequency of genomic alterations dominated by CEP55 mutations was highest in uterine corpus endometrial carcinoma (4.91%, 26/529), followed by diffuse large B-cell lymphoma (2.08%, 1/48); and those dominated by amplification in uterine carcinosarcoma (3.51%, 2/57), followed by uterine corpus endometrial carcinoma (0.76%, 4/529); and those dominated by deep deletions in prostate adenocarcinoma (2.23%, 11/494), followed by diffuse large B-cell lymphoma (2.08%, 1/48), recommending that we should pay attention to the relationship between CEP55 mutations and tumor development. This evidence concerns the gene CEP55 and neoplasm.